Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Reid W. Merryman(Harvard University), Jason T. Romancik(Emory University), Lori Dahncke(Hackensack Meridian Health), Justin Kline(University of Chicago), Mehdi Hamadani(Medical College of Wisconsin), Geoffrey Shouse(City Of Hope National Medical Center), Tatyana Feldman(Hackensack University Medical Center), Mohamad Mohty(Sorbonne Université), Luca Castagna(Humanitas University), Gunjan L. Shah(Cornell University), Didier Blaise(Institut Paoli-Calmettes), Yago Nieto(The University of Texas MD Anderson Cancer Center), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Anurag K. Singh(University Medical Center), Amer Beitinjaneh(University of Miami), Sally Arai(Stanford Medicine), Michael Byrne(Vanderbilt University Medical Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Chloé Spilleboudt(Institut Jules Bordet), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), Paolo Corradini(Gruppo di Ricerca Geriatrica), Guillaume Manson(Hôpital Pontchaillou), Jean‐Marc Schiano de Colella(Centre de Recherche en Cancérologie de Marseille), Stephen M. Ansell(Mayo Clinic), Taiga Nishihori(Moffitt Cancer Center), Stephen D. Smith(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Matthew J. Frigault(Harvard University), Beatrice Casadei(Istituto di Ematologia di Bologna), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), A. Stamatoulas(University of Bern), Rémy Duléry(Dana-Farber Cancer Institute), Lazaros J. Lekakis(University of Miami Hospital), Anthony V. Serritella(University of Chicago), Talha Badar(Mayo Clinic in Florida), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Julio C. Chávez(Moffitt Cancer Center), Dipenkumar Modi(Wayne State University), Corentin Orvain(Centre Hospitalier Universitaire d'Angers), Vincent T. Ho(Dana-Farber Cancer Institute), Robert Lowsky(Stanford Blood Center), Kamal Bouabdallah(Université de Bordeaux), Roch Houot(Centre Hospitalier Universitaire de Rennes), Uttam K. Rao(Sarah Cannon), Michael A. Spinner(Stanford Medicine), Marie-Pierre Moles-Moreau(Centre Hospitalier Universitaire d'Angers), Ryan C. Lynch(Seattle Cancer Care Alliance)
Cited by 83
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k